These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 10918072)

  • 61. Modulation of P-glycoprotein-mediated drug transport by alterations in lipid fluidity of rat liver canalicular membrane vesicles.
    Sinicrope FA; Dudeja PK; Bissonnette BM; Safa AR; Brasitus TA
    J Biol Chem; 1992 Dec; 267(35):24995-5002. PubMed ID: 1360981
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Reversal of P-glycoprotein-associated multidrug resistance by ivermectin.
    Pouliot JF; L'Heureux F; Liu Z; Prichard RK; Georges E
    Biochem Pharmacol; 1997 Jan; 53(1):17-25. PubMed ID: 8960059
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Multidrug-resistance transporters.
    Silverman JA
    Pharm Biotechnol; 1999; 12():353-86. PubMed ID: 10742982
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Lipophilic cations: a group of model substrates for the multidrug-resistance transporter.
    Gros P; Talbot F; Tang-Wai D; Bibi E; Kaback HR
    Biochemistry; 1992 Feb; 31(7):1992-8. PubMed ID: 1371401
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Expression of the MDR1 and MDR3 gene products in acute and chronic leukemias.
    Arai Y; Masuda M; Sugawara I; Arai T; Motoji T; Tsuruo T; Oshimi K; Mizoguchi H
    Leuk Res; 1997 Apr; 21(4):313-9. PubMed ID: 9150348
    [TBL] [Abstract][Full Text] [Related]  

  • 66. ATP hydrolysis-dependent multidrug efflux transporter: MDR1/P-glycoprotein.
    Kimura Y; Matsuo M; Takahashi K; Saeki T; Kioka N; Amachi T; Ueda K
    Curr Drug Metab; 2004 Feb; 5(1):1-10. PubMed ID: 14965247
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Reversal of adriamycin resistance in human mammary cancer cells by small interfering RNA of MDR1 and MDR3 genes.
    Xiao L; Gao R; Lu S; Ren L; Wang Z
    J Huazhong Univ Sci Technolog Med Sci; 2006; 26(6):735-7. PubMed ID: 17357504
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Peroxisome proliferator-activated receptor α activates human multidrug resistance transporter 3/ATP-binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion.
    Ghonem NS; Ananthanarayanan M; Soroka CJ; Boyer JL
    Hepatology; 2014 Mar; 59(3):1030-42. PubMed ID: 24122873
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Mechanisms of multidrug resistance in HL60 cells. Analysis of resistance associated membrane proteins and levels of mdr gene expression.
    McGrath T; Latoud C; Arnold ST; Safa AR; Felsted RL; Center MS
    Biochem Pharmacol; 1989 Oct; 38(20):3611-9. PubMed ID: 2573357
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo.
    De Vera AA; Gupta P; Lei Z; Liao D; Narayanan S; Teng Q; Reznik SE; Chen ZS
    Cancer Lett; 2019 Feb; 442():91-103. PubMed ID: 30391357
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies.
    Scheffer GL; Kool M; Heijn M; de Haas M; Pijnenborg AC; Wijnholds J; van Helvoort A; de Jong MC; Hooijberg JH; Mol CA; van der Linden M; de Vree JM; van der Valk P; Elferink RP; Borst P; Scheper RJ
    Cancer Res; 2000 Sep; 60(18):5269-77. PubMed ID: 11016657
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Drug-protein hydrogen bonds govern the inhibition of the ATP hydrolysis of the multidrug transporter P-glycoprotein.
    Chufan EE; Kapoor K; Ambudkar SV
    Biochem Pharmacol; 2016 Feb; 101():40-53. PubMed ID: 26686578
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters.
    Cardarelli CO; Aksentijevich I; Pastan I; Gottesman MM
    Cancer Res; 1995 Mar; 55(5):1086-91. PubMed ID: 7866993
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Inhibitors of P-glycoprotein-mediated daunomycin transport in rat liver canalicular membrane vesicles.
    Kwon Y; Kamath AV; Morris ME
    J Pharm Sci; 1996 Sep; 85(9):935-9. PubMed ID: 8877882
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein.
    Baltes S; Gastens AM; Fedrowitz M; Potschka H; Kaever V; Löscher W
    Neuropharmacology; 2007 Feb; 52(2):333-46. PubMed ID: 17045309
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Interaction of cyclosporin derivatives with the ATPase activity of human P-glycoprotein.
    Watanabe T; Kokubu N; Charnick SB; Naito M; Tsuruo T; Cohen D
    Br J Pharmacol; 1997 Sep; 122(2):241-8. PubMed ID: 9313931
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Competitive and non-competitive inhibition of the multidrug-resistance-associated P-glycoprotein ATPase--further experimental evidence for a multisite model.
    Garrigos M; Mir LM; Orlowski S
    Eur J Biochem; 1997 Mar; 244(2):664-73. PubMed ID: 9119038
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Differential sensitivities of the human ATP-binding cassette transporters ABCG2 and P-glycoprotein to cyclosporin A.
    Ejendal KF; Hrycyna CA
    Mol Pharmacol; 2005 Mar; 67(3):902-11. PubMed ID: 15598974
    [TBL] [Abstract][Full Text] [Related]  

  • 79. In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2.
    Marchetti S; Oostendorp RL; Pluim D; van Eijndhoven M; van Tellingen O; Schinkel AH; Versace R; Beijnen JH; Mazzanti R; Schellens JH
    Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3307-13. PubMed ID: 18089724
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Role of P-glycoprotein in the intestinal absorption of tanshinone IIA, a major active ingredient in the root of Salvia miltiorrhiza Bunge.
    Yu XY; Lin SG; Zhou ZW; Chen X; Liang J; Liu PQ; Duan W; Chowbay B; Wen JY; Li CG; Zhou SF
    Curr Drug Metab; 2007 May; 8(4):325-40. PubMed ID: 17504222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.